Evaluation of 99Mtc-Hydrazinonicotinamide-tyr3-octreotide SPECT/CT in Detection of Liver Metastases in Patients with Neuroendocrine Tumors

JIANGJin-jin,XUJun-yan,XUXiao-ping,YANGZhong-yi,ZHANGJian-gang,LUXiao-ling,ZHANGYing-jian
2014-01-01
Abstract:Objective To evaluate the value of 99mTc-hydrazinonicotinamide-Tyr3-octreotide (99mTc-HYNIC-TOC) in detection of liver metastases in patients with neuroendocrine tumors. Methods 99mTc-HYNIC-TOC imaging data of 17 neuroendocrine tumor patients with liver metastases were analyzed retrospectively, including 13 rectal, 3 pancreatic and 1 abdominal neuroendocrine tumors. Total body imaging and SPECT/CT imaging were obtained 2 h after intravenous injection of 10-15 mCi 99mTc-HYNIC-TOC. Results 76.5% (13/17) of neuroendocrine tumor patients with liver metastases were positive on 99mTc-HYNIC-TOC imaging. The average target/non-target (T/NT) value of positive lesions was 3.73±2.57 (1.50~13.03, n=46). The detection rate for all the lesions was 92.0% (46/50). The detection rates of TOC imaging with low-dose CT and normal-dose CT were 40.0%(20/50) and 64.7%(11/17) respectively. The size of the smallest lesion detected was only 7 mm, with T/NT value of 2.68. Besides, SPECT/CT scan could provide more correct information than planar imaging. Conclusion 99mTc-HYNIC-TOC SPECT/CT is an excellent method for detection of liver metastases in the patients with neuroendocrine tumors.
What problem does this paper attempt to address?